Abstract
Background Adipokines derived from adipocytes are one of the important
factors that act as circulating regulators of bone metabolism. Complement
C1q/tumor necrosis factor-related protein-3 (CTRP3), a paralog of
adiponectin, is are member of the CTRP superfamily. The aim of this study was to
investigate the role of serum CTRP3 in the development of osteoporosis in
patients with primary hyperparathyroidism.
Methods This study included 53 patients with diagnosed primary
hyperparathyroidism and 30 healthy controls. Laboratory tests for the diagnosis
of primary hyperparathyroidism and serum levels of CTRP3 measured for all
patients. Bone mineral density was obtained on lumbar spine 1 and 4 by dual
energy X-ray absorptiometry.
Results Serum CTRP3 levels were lower in patients with primary
hyperparathyroidism than in the control group (p<0.001). In addition,
primary hyperparathyroidism patients are were divided into two groups as, with
and without osteoporosis; the levels of CTRP3 were lower in patients with
osteoporosis than in patients without osteoporosis (p=0.004). In
logistic regression analysis, only CTRP3 levels independently determined the
patients to be osteoporosis (p<0.05). According to this analysis,
decreased CTRP3 (per 1 ng/mL) levels were found to increase the
risk of patients for osteoporosis by 6.9%. When the CTRP3 cut-off values
were taken as 30 ng/mL, it determined osteoporosis with
76.4% sensitivity and 73.2% specificity. CTRP3 and urine calcium
levels were independently associated with T score in dual energy X-ray
absorptiometry.
Conclusions CTRP3 levels were significantly decreased in patients with
primary hyperparathyroidism, and it is also related to osteoporosis.
Key words
adiponectin - bone mineral density - adipokine - osteopenia - dual energy X-ray absorptiometry
